Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleSupplement

Iodine Symporter Targeting with 124I/131I Theranostics

James Nagarajah, Marcel Janssen, Philipp Hetkamp and Walter Jentzen
Journal of Nuclear Medicine September 2017, 58 (Supplement 2) 34S-38S; DOI: https://doi.org/10.2967/jnumed.116.186866
James Nagarajah
1Department of Radiology and Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; and
2Department of Nuclear Medicine, University of Duisburg–Essen, Duisburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcel Janssen
1Department of Radiology and Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philipp Hetkamp
2Department of Nuclear Medicine, University of Duisburg–Essen, Duisburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Walter Jentzen
2Department of Nuclear Medicine, University of Duisburg–Essen, Duisburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 58 no. Supplement 2 34S-38S
DOI 
https://doi.org/10.2967/jnumed.116.186866
PubMed 
28864610

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication March 16, 2017
  • Accepted for publication May 31, 2017
  • Published online September 1, 2017.

Copyright & Usage 
© 2017 by the Society of Nuclear Medicine and Molecular Imaging.

Author Information

  1. James Nagarajah1,2,
  2. Marcel Janssen1,
  3. Philipp Hetkamp2 and
  4. Walter Jentzen2
  1. 1Department of Radiology and Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; and
  2. 2Department of Nuclear Medicine, University of Duisburg–Essen, Duisburg, Germany
  1. For correspondence or reprints contact: James Nagarajah, Department of Radiology and Nuclear Medicine, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands. E-mail: james.nagarajah{at}radboudumc.nl
View Full Text

Statistics from Altmetric.com

Cited By...

  • 42 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Radiotheranostics: a roadmap for future development
    Ken Herrmann, Markus Schwaiger, Jason S Lewis, Stephen B Solomon, Barbara J McNeil, Michael Baumann, Sanjiv S Gambhir, Hedvig Hricak, Ralph Weissleder
    The Lancet Oncology 2020 21 3
  • ICRU REPORT 96, Dosimetry-Guided Radiopharmaceutical Therapy
    George Sgouros, Wesley E. Bolch, Arturo Chiti, Yuni K. Dewaraja, Dimitris Emfietzoglou, Robert F. Hobbs, Mark Konijnenberg, Katarina Sjögreen-Gleisner, Lidia Strigari, Tzu-Chen Yen, Roger W. Howell
    Journal of the ICRU 2021 21 1
  • Current Treatment Strategies in Metastasized Differentiated Thyroid Cancer
    Michael C. Kreissl, Marcel J.R. Janssen, James Nagarajah
    Journal of Nuclear Medicine 2019 60 1
  • Redifferentiation of a BRAFK601E-Mutated Poorly Differentiated Thyroid Cancer Patient with Dabrafenib and Trametinib Treatment
    Sophie Leboulleux, Corinne Dupuy, Ludovic Lacroix, Marie Attard, Serena Grimaldi, Raphaël Corre, Marcel Ricard, Sarah Nasr, Amandine Berdelou, Julien Hadoux, Dana Hartl, Marie Terroir, Eric Baudin, Martin Schlumberger, Abir Al Ghuzlan
    Thyroid 2019 29 5
  • [68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment
    Steffie M. B. Peters, Regina Hofferber, Bastiaan M. Privé, Maarten de Bakker, Martin Gotthardt, Marcel Janssen, Frank de Lange, Constantijn H. J. Muselaers, Niven Mehra, J. Alfred Witjes, Pedro F. Costa, James Nagarajah, Mark W. Konijnenberg, Walter Jentzen
    European Journal of Nuclear Medicine and Molecular Imaging 2022 49 4
  • Theranostic Concepts: More Than Just a Fashion Trend—Introduction and Overview
    Ken Herrmann, Steven M. Larson, Wolfgang A. Weber
    Journal of Nuclear Medicine 2017 58 Supplement 2
  • Molecular Imaging and Theragnostics of Thyroid Cancers
    Luca Giovanella, Desiree’ Deandreis, Alexis Vrachimis, Alfredo Campenni, Petra Petranovic Ovcaricek
    Cancers 2022 14 5
  • Production Review of Accelerator-Based Medical Isotopes
    Yiwei Wang, Daiyuan Chen, Ricardo dos Santos Augusto, Jixin Liang, Zhi Qin, Juntao Liu, Zhiyi Liu
    Molecules 2022 27 16
  • Radioimmunoimaging and targeting treatment in an immunocompetent murine model of triple‐negative breast cancer using radiolabeled anti–programmed death‐ligand 1 monoclonal antibody
    Xiaoxi Pang, Meng Liu, Rongfu Wang, Xuhe Liao, Ping Yan, Chunli Zhang
    Journal of Labelled Compounds and Radiopharmaceuticals 2018 61 11
  • Radioiodine based biomedical carriers for cancer theranostics
    Jingru Guo, Hehua Xiong, Huihui Liu, Tao Zhang, Xiaolian Sun
    Coordination Chemistry Reviews 2023 497

Article usage

Article usage:

No statistics are available.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 58 (Supplement 2)
Journal of Nuclear Medicine
Vol. 58, Issue Supplement 2
September 1, 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Iodine Symporter Targeting with 124I/131I Theranostics
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Iodine Symporter Targeting with 124I/131I Theranostics
James Nagarajah, Marcel Janssen, Philipp Hetkamp, Walter Jentzen
Journal of Nuclear Medicine Sep 2017, 58 (Supplement 2) 34S-38S; DOI: 10.2967/jnumed.116.186866

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Iodine Symporter Targeting with 124I/131I Theranostics
James Nagarajah, Marcel Janssen, Philipp Hetkamp, Walter Jentzen
Journal of Nuclear Medicine Sep 2017, 58 (Supplement 2) 34S-38S; DOI: 10.2967/jnumed.116.186866
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • CLINICAL USE OF THERANOSTIC AGENTS OTHER THAN IODINE
    • THERANOSTICS WITH IODINE
    • IODINE METABOLISM
    • THERANOSTICS WITH IODINE IN NONTHYROIDAL CANCER
    • IODINE AND BREAST CANCER
    • CONCLUSION
    • DISCLOSURE
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Current Treatment Strategies in Metastasized Differentiated Thyroid Cancer
  • Theranostic Concepts: More Than Just a Fashion Trend--Introduction and Overview
  • Google Scholar

More in this TOC Section

  • The Role of Total-Body PET in Drug Development and Evaluation: Status and Outlook
  • Melanin-Targeting Radiotracers and Their Preclinical, Translational, and Clinical Status: From Past to Future
  • Advancing Global Nuclear Medicine: The Role and Future Contributions of China
Show more Supplement

Similar Articles

Keywords

  • iodine theranostics
  • sodium–iodine symporter
  • redifferentiation
  • trametinib
  • breast cancer
SNMMI

© 2025 SNMMI

Powered by HighWire